Novel compounds as ck2 inhibitors
AssigneeCambridge Enterprise Limited
InventorsPaul Glossop, Marko Juhana Hyvonen, Paul Brear, David Robert Spring
Life of this patent
Estimating the term…
Loading patent…
AssigneeCambridge Enterprise Limited
InventorsPaul Glossop, Marko Juhana Hyvonen, Paul Brear, David Robert Spring
Estimating the term…
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein RL is selected from one of formulae Ic, Ie or If shown below:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein RL is selected from one of formulae shown below:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Ra and Re are both hydrogen.
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Rb and Rd are each independently selected from hydrogen, halo, cyano, (1-4C)alkyl, (3-6C)cycloalkyl,
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein one of Rb and Rd is hydrogen or halogen and the other is selected from hydrogen, fluoro, chloro cyano, methyl, ethyl, methoxy, ethoxy, —C(O)NH2, —CH2-oxazole, —CH2OH, —CH2CN, —CH2CH2OH, —CF3, —OCF3, —O—CH2CH2OH or —CH2—C(O)NH2.
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Rc is selected from hydrogen, halo, cyano, —C(O)NH2, (1-4C)alkyl, (3-6C)cycloalkyl, -(1-4C)alkoxy,
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Rc is selected from hydrogen, —CF3, —OCF3, cyclopropyl, phenyl, —O-cyclobutyl or -phenyl-CH2—OH;
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein RR is selected from one of formulae Im or In shown below:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is a 5- or 6-membered heteroaryl ring comprising one, two, three or four heteroatoms selected from N, O or S which is optionally substituted on any available carbon atom by one or more R1A substituent groups and on any available nitrogen atom by one or more R1B substituent groups;
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is selected from:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein each R1A group present is selected from hydroxy, cyano, amino, chloro, fluoro, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl;
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein each R1B group is methyl.
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is selected from:
A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is selected from:
A compound according to any one of the preceding claims, or a salt, hydrate or solvate thereof, wherein the compound is selected from any one of the following:
Dependencies are inferred from the claim text.